
Inner Mongolia Furui Medical Science is a liver-disease prevention and treatment company with core product FibroScan and Chinese medicine 复方鳖甲软肝片.
fu-rui.comCrawled Nov 13, 2026
Furei Holdings leads the liver disease treatment sector, offering comprehensive fatty liver solutions. Its FibroScan device, the first to use instant elasticity imaging, is included in multiple international liver disease guidelines.
Furei Holdings provides liver health assessments using non-invasive testing, including FibroScan, the first device to apply instant elasticity imaging for liver fibrosis diagnosis.
This section provides the latest company updates from Foresight Group, including recent activities, news, and industry developments.
Foresight Group was founded in 1998, with its headquarters in Beijing and subsidiaries in France, Spain, Germany, the United States, and Hong Kong. The company listed on the Shenzhen Stock Exchange’s Growth Enterprise Market in 2010 with the stock code 300049. Foresight Group is the leading brand in liver health management, focusing on managed healthcare services, including screening, assessment, management, treatment, and insurance for high-risk liver cancer populations.
Foresight Group promotes sustainable development in environmental, social, and governance (ESG) practices. Its plantations emphasize ecological protection, while its social responsibility initiatives include employee health and safety, community development, and philanthropy. The company maintains transparent governance and information disclosure to protect stakeholders' interests.
Furei Holdings is based in Beijing, China, with contact details including a phone number, address, and email.
Furei Holdings (stock code: 300049) specializes in liver disease, providing FibroScan and treatment drugs. The company offers integrated screening, diagnosis, treatment, management, and insurance services for patients and doctors.
Furei Medical (stock code: 300049) focuses on liver disease with a mission to keep families away from liver cancer. It offers FibroScan and liver treatment drugs, delivering end-to-end screening, diagnosis, treatment, management, and insurance solutions.
Inner Mongolia Furui Medical Science Co., Ltd. reports **CNY 1,141.44 million in sales and revenue** for the nine months ended September 30, 2026. This marks a slight increase compared to the same period in the prior year, when figures stood at **CNY 1,101.04 million**. The company provides earnings updates covering its financial performance over the specified period.
Inner Mongolia Furui Medical Science Co experiences a **5.90% stock price decline** on a single trading day. The drop follows unspecified market conditions or company developments. The company operates in the medical science sector, though no specific drivers for the decline are detailed in the report.
Inner Mongolia Furui Medical Science cancels its planned purchase of a 4.68% stake in Echosens SAS from five sellers, including Laurent Sandrin, Raphael Durand, and Sino French Midcap Fund. The deal involves Cathay Capital Private Equity as the fund manager. The company withdraws from the transaction without further details provided.
Inner Mongolia Furui Medical Science Co., Ltd acquires a 4.68% stake in Echosens SAS for €20.1 million. The transaction involves purchasing shares from five sellers, including Sino French Midcap Fund and key individuals like Laurent Sandrin and Raphael Durand. The deal expands Furui’s equity position in the French medical technology firm.
Inner Mongolia Furui Medical Science’s Luxembourg subsidiary is investing **19.6 million euros** in **Median Technologies**, a French company. The funding supports an unspecified strategic partnership or expansion. Median Technologies operates in the medical sciences sector, aligning with Furui’s focus on healthcare innovations.